$28.7MRank #1172 on ASXHealthcareMedical - Devices
Prices updated 23 June 2026, 8:40 am AEST · Data: Financial Modeling Prep
Market Cap
$28.7M
Volume
224K
P/E Ratio
-1.4
EPS
-$0.0109
Dividend Yield
0.00%
52-Week High
$0.095
52-Week Low
$0.028
Beta
0.108
Control Bionics (ASX: CBL) is an Australian-listed company in the Healthcare sector with a market capitalisation of $28.7M and the 1172nd-largest security on the ASX by market capitalisation. The CBL share price is $0.09, down 1.10% today and up 203.33% over the past 12 months. Shares have traded between $0.028 and $0.095 over the past 52 weeks. In its most recent reported period (ending 31 Dec 2025), Control Bionics reported revenue of $2.8M and a net loss of $3.6M.
Charts
$0.09
24H Range
$0.086
$0.091
52-Week Range
$0.028
$0.095
About Control Bionics Limited
Operating in Australia and North America, Control Bionics Limited and its subsidiaries specialize in the innovation, development, and market introduction of sophisticated assistive communication technologies. The company's offerings include the NeuroNode Trilogy and NeuroNode3 systems, which empower individuals facing speech and mobility challenges to control computers for speech generation, electronic correspondence, leisure activities, and remote operation of other devices. Control Bionics also provides Cosmos Connect, a versatile interface capable of managing diverse equipment like wheelchairs, robotic dining aids, and gaming consoles. Additionally, they offer Uno Touch, a dedicated speech-generating device, alongside various other sensors for a broad spectrum of uses. Founded in 2005, the entity was initially named Control Bionics Holdings Pty Limited before rebranding as Control Bionics Limited in September 2020. The company's base of operations is situated in Camberwell, Australia.
What is the Control Bionics (ASX: CBL) share price?
The CBL share price is $0.09, down 1.10% for the day, based on the latest available ASX market data.
What is Control Bionics's market capitalisation?
Control Bionics has a market capitalisation of $28.7M, making it the 1172nd-largest security listed on the ASX.
Does Control Bionics pay a dividend?
CBL does not currently have a dividend on record. Some companies, particularly those reinvesting in growth or not yet profitable, do not pay dividends.
Is Control Bionics profitable?
In its most recent reported period (ending 31 Dec 2025), CBL reported revenue of $2.8M and a net loss of $3.6M.
How many CBL shares are on issue?
Control Bionics has approximately 319,403,156 shares on issue, based on its market capitalisation of $28.7M and current share price.
What sector is Control Bionics in?
Control Bionics is classified in the Healthcare sector, within the Medical - Devices industry on the ASX.
When did Control Bionics list on the ASX?
Control Bionics listed on the Australian Securities Exchange on 6 Dec 2020.
CBL is held by 2 ASX-listed funds tracked on this site. The largest allocation is in Vanguard MSCI International Small Companies Index ETF (ASX: VISM) at 0.01% of its portfolio.
